Novartis Acquires Vedere Bio, an Optogenetics AAV Gene Therapy Company, for up to $280M
Novartis AG acquired Vedere Bio, Inc., a stealth-stage start-up focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision.
- Gene Therapy, Cell Therapy
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com